BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced on October 6, 2025 that it has entered into definitive agreements with accredited and institutional investors for a registered direct offering of 678,125 shares of its common stock at an offering price of $1.60 per share. The gross proceeds from the offering are $1.085 million, before placement agent fees and other estimated expenses. The transaction also includes unregistered warrants covering 75% of the shares, allowing investors to purchase up to 508,594 additional shares at an exercise price of $2.75 per share, exercisable six months after issuance and expiring five years later.
The company stated that the net proceeds will be used to support its clinical development of the lead cell therapy candidate BRTX‑100, advance pre‑clinical research for its ThermoStem metabolic program, expand its commercial biocosmeceuticals platform, and provide general corporate purposes and working capital. CEO Lance Alstodt emphasized that the capital raise, combined with existing cash, positions BRTX to continue executing on its strategic goals.
The closing of the offering is expected to occur on or about October 8, 2025, under a shelf registration statement on Form S‑3 that was previously filed and declared effective by the SEC. The announcement represents a significant financing event for BRTX, providing additional liquidity to fund its growth initiatives and maintain momentum in its regenerative medicine pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.